NFL Biosciences SA (EPA: ALNFL)

Market Cap	19.61M
Revenue	n/a
Net Income	n/a
Shares Out	9.71M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,554
Open	2.080
Previous Close	2.020
Day's Range	2.025 - 2.120
52-Week Range	1.330 - 3.280
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 28, 2025

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Country: France
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALNFL